Raymond E. Cabillot Sells 7,674 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 7,674 shares of Pro-Dex stock in a transaction on Monday, March 10th. The shares were sold at an average price of $45.00, for a total transaction of $345,330.00. Following the completion of the sale, the director now owns 310,978 shares in the company, valued at approximately $13,994,010. This trade represents a 2.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pro-Dex Price Performance

Shares of NASDAQ:PDEX opened at $47.78 on Wednesday. Pro-Dex, Inc. has a fifty-two week low of $16.83 and a fifty-two week high of $59.60. The business has a 50-day simple moving average of $39.93 and a two-hundred day simple moving average of $37.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The firm has a market cap of $155.81 million, a price-to-earnings ratio of 23.77 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the period. Bank of New York Mellon Corp purchased a new stake in Pro-Dex in the fourth quarter worth $202,000. Trexquant Investment LP purchased a new stake in Pro-Dex in the fourth quarter worth $252,000. Integrated Quantitative Investments LLC purchased a new position in shares of Pro-Dex during the fourth quarter valued at $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Pro-Dex during the fourth quarter valued at $255,000. 15.28% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 3rd.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.